Adial Pharmaceuticals Inc. (ADIL)
NASDAQ (CM) NASDAQ (CM) Primary Summary
ADIL Chart
Adial Pharmaceuticals (ADIL) Upgraded to Strong Buy: Here's Why
Adial Pharmaceuticals (ADIL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Adial Pharmaceuticals (ADIL) Upgraded to Buy: Here's What You Should Know
Adial Pharmaceuticals (ADIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference
Glen Allen, VA, October 23, 2024 – PRISM MediaWire – Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals Inc. Dividends
Adial Pharmaceuticals Inc. Earnings
| 11 Nov 2025 (In 3 months) Date | | - Cons. EPS | - EPS |
| 12 Aug 2025 Date | | - Cons. EPS | - EPS |
| 12 Aug 2025 Date | | - Cons. EPS | - EPS |
| 12 May 2025 Date | | - Cons. EPS | - EPS |
| 31 Mar 2025 Date | | - Cons. EPS | - EPS |
| 11 Nov 2025 (In 3 months) Date | | - Cons. EPS | - EPS |
| 12 Aug 2025 Date | | - Cons. EPS | - EPS |
| 12 Aug 2025 Date | | - Cons. EPS | - EPS |
| 12 May 2025 Date | | - Cons. EPS | - EPS |
| 31 Mar 2025 Date | | - Cons. EPS | - EPS |
Adial Pharmaceuticals Inc. (ADIL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Adial Pharmaceuticals Inc. ever had a stock split?
Adial Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Cary John Claiborne MBA CEO | NASDAQ (CM) Exchange | 00688A106 Cusip |
| US Country | 5 Employees | - Last Dividend | 7 Aug 2023 Last Split | 30 Jul 2018 IPO Date |
Overview
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company with a focus on developing therapeutics for the treatment or prevention of addiction and related disorders. Founded in 2010, the company is nestled in Charlottesville, Virginia, where it dedicates its efforts to addressing the growing needs within the addiction treatment landscape. Through rigorous research and development practices, Adial Pharmaceuticals strives to bring innovative solutions to market, aimed at tackling the challenges faced by individuals struggling with substance abuse and pain management issues without relying on opioids.
Products and Services
- AD04:
As the lead product in Adial Pharmaceuticals' pipeline, AD04 represents a significant advancement in the treatment of alcohol use disorder (AUD). AD04 operates as a serotonin-3 antagonist, engaging in the complex neurochemistry of addiction to potentially offer a novel treatment approach for those battling alcohol dependence. Currently, this drug is in Phase III clinical trials, embodying the company’s commitment to addressing the pervasive issue of AUD with cutting-edge science.
- Non-opioid Pain Reduction Candidates:
In response to the opioid crisis and the increasing need for safer pain management solutions, Adial Pharmaceuticals is also in the process of developing drug candidates designed for non-opioid pain reduction. These candidates are being researched with the aim of providing effective pain relief while mitigating the risk of addiction, dependency, and side effects commonly associated with opioid painkillers. This initiative reflects Adial's broader mission to combat addiction and support healthier communities through innovative therapeutic alternatives.
- Drug Candidates for Other Diseases and Disorders:
Expanding its reach beyond addiction and pain management, Adial Pharmaceuticals is actively exploring the development of drug candidates for a variety of diseases and disorders. This extensive research and development effort underscores the company’s dedication to leveraging scientific advancements for the creation of transformative treatments. By casting a wider net, Adial aims to address unmet medical needs across different therapeutic areas, further solidifying its role in the pharmaceutical industry as a leader in innovation and patient care.
Contact Information
